Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03552471
Title Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field